Stan rekrutacji pochodzi z rejestrów badań i może się zmienić szybciej, niż zaktualizuje go sponsor. Nasz doradca sprawdzi aktualny stan w wybranym ośrodku. Nie publikujemy nazwisk lekarzy ani ich danych kontaktowych.
Cel badania
Opis z rejestru (w języku angielskim):
The purpose of the study: obtaining knowledge about the impact of Snoezelen® therapy on the health of adults suffering from schizophrenia and requiring permanent institutional care, adults suffering from schizophrenia and adults (women) addicted to alcohol.
The main questions it aims to answer are:
Does Snoezelen therapy improve the health of adults suffering from schizophrenia and requiring permanent institutional care, adults suffering from schizophrenia and adults (women) addicted to alcohol?
The participant will participate in Snoezelen® therapy for 6 or 12 weeks, 2 times a week (30 minutes each session).
Leczenie w badaniu
Lek / interwencja
Rola
Postać, podanie
Snoezelen® therapy for 6 weeks
Inne
Snoezelen® therapy for 12 weeks
Inne
Kryteria udziału
Kryteria w języku angielskim, tak jak w rejestrze.
Kryteria włączenia kto może wziąć udział (7)
Adults suffering from schizophrenia requiring permanent institutional care, N=40
Inclusion criteria:
women and men aged ≥ 18 years,
consent of the patient or legal guardian to participate in the study,
schizophrenia clinically confirmed for at least 5 years, with predominance of negative symptoms,
stable drug therapy (treatment unchanged for at least 3 months)
ability to understand and follow the therapist's instructions,
functional ability of everyday life on the Barthel scale below 40 points,
Kryteria wyłączenia kto nie może wziąć udziału (44)
lack of consent to participate in the study;
pregnancy;
general contraindications (acute inflammatory and febrile diseases, venous thrombosis, unstable arterial hypertension, early condition after contrast computed tomography, early condition after lumbar puncture, general serious condition of the patient);
unstable or untreated epilepsy, based on EEG;
exacerbation of the main disease (acute psychosis, severe anxiety, tendency to active aggression, etc.);
active cancer disease;
diseases of the nervous system (neuropathies, stroke, damage to the cerebellum, labyrinth, Parkinson's disease) causing altered sensitivity to stimuli;
diseases and illnesses of the musculoskeletal system that disturb the body's balance and the mobility of the limbs.
Adults (men) suffering from schizophrenia, N=40
Inclusion criteria:
men aged ≥ 18 years,
consent of the patient or legal guardian to participate in the study,
clinically confirmed schizophrenia with predominance of negative symptoms,
stable drug therapy (treatment unchanged for at least 1 month),
ability to understand and follow the therapist's instructions,
functional ability of everyday life on the Barthel scale above 40 points,
Exclusion criteria:
lack of consent to participate in the study;
general contraindications (acute inflammatory and febrile diseases, venous thrombosis, unstable arterial hypertension, early condition after contrast computed tomography, early condition after lumbar puncture, general serious condition of the patient);
unstable or untreated epilepsy, based on EEG;
exacerbation of the main disease (acute psychosis, severe anxiety, tendency to active aggression, etc.);
active cancer disease;
diseases of the nervous system (neuropathies, stroke, damage to the cerebellum, labyrinth, Parkinson's disease) causing altered sensitivity to stimuli; diseases and illnesses of the musculoskeletal system disturbing body balance and limb mobility.
Adults (women) addicted to alcohol, N= 60
Inclusion criteria:
female gender;
age ≥ 18 years;
consent of the patient or legal guardian to participate in the study;
alcohol dependence syndrome (F10.2 according to ICD-10);
history of depressive and anxiety symptoms;
ability to understand and follow the therapist's instructions;
functional ability of everyday life on the Barthel scale above 40 points.
Exclusion criteria:
lack of consent to participate in the study;
pregnancy;
psychoactive substances other than alcohol;
exacerbation of the main disease (acute psychosis, severe anxiety, tendency to active aggression, etc.);
mental illnesses other than depression and anxiety disorders;
psychotic diseases (F20- schizophrenia and other schizophrenic disorders);
general contraindications (acute inflammatory and febrile diseases, venous thrombosis, unstable arterial hypertension, early condition after contrast computed tomography, early condition after lumbar puncture, general serious condition of the patient);
unstable or untreated epilepsy, based on EEG;
active cancer disease;
diseases of the nervous system (neuropathies, stroke, damage to the cerebellum, labyrinth, Parkinson's disease) causing altered sensitivity to stimuli;
severe cognitive impairment;
diagnosis of autism and ADHD;
PTSD;
intellectual disability (diagnosis F70 - F79);
diseases and illnesses of the musculoskeletal system that disturb the body's balance and the mobility of the limbs.
To główne kryteria z rejestru. Pełną listę i ostateczną decyzję o udziale ustala lekarz prowadzący badanie.
Zapytaj o udział w tym badaniu
Zadzwoń, a nasz doradca ds. badań sprawdzi z Tobą wstępnie kryteria i pomoże skontaktować się z ośrodkiem. Kwalifikację zawsze przeprowadza lekarz w ośrodku. Udział w badaniu jest bezpłatny i dobrowolny.
A Study to Evaluate the Long-term Safety and Tolerability of Xanomeline and Trospium Chloride for the Treatment of Psychiatric Disorders in Children and Adolescents
A Phase III, 52-week, prospective, randomized, double-blind, placebo-controlled, parallel-group, multi-center study, with a primary efficacy endpoint at 12 weeks, to determine…
Informacje pochodzą z publicznych rejestrów badań klinicznych (CTIS - Unia Europejska, ClinicalTrials.gov - USA) i są aktualizowane codziennie. Mogą różnić się od aktualnego stanu w ośrodku. Ostateczną kwalifikację do badania zawsze przeprowadza lekarz w ośrodku badawczym. Stan na 2 października 2026.